2024 MDA Clinical and Scientific Conference Initial results of the Phase 2 Open-Label Extension Study of AOC 1001 in Adults with Myotonic Dystrophy Type 1: MARINA-OLE™ AOC 1001-mediated Reduction of DMPK Leads to Increase in Functional MBNL Levels, Improving Muscle Function in Patients with DM1 AOC 1044 as a Novel Therapeutic Approach for DMD Patients Amenable to Exon 44 Skipping: EXPLORE44 Phase 1/2 Healthy Volunteer Data Targeting DUX4 for Silencing with AOC for the Treatment of FSHD Increasing Diversity in Clinical Trial Participation: An Exploration of Clinical Trial Site Engagement